|
Synonyms: XmAb5871
Compound class:
Antibody
Comment: Obexelimab (XmAb5871) is an anti-CD19 monoclonal antibody [3-4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use ![]() |
| Obexelimab (XmAb5871) was progressed as a clinical candidate. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05662241 | A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease | Phase 3 Interventional | Zenas BioPharma (USA), LLC | ||
| NCT05786573 | A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) | Phase 3 Interventional | Zenas BioPharma (USA), LLC | ||
| NCT06559163 | A Study of Obexelimab in Patients With Systemic Lupus Erythematosus | Phase 2 Interventional | Zenas BioPharma (USA), LLC | ||
| NCT06564311 | A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) | Phase 2 Interventional | Zenas BioPharma (USA), LLC | ||
| NCT02725476 | Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD) | Phase 2 Interventional | Xencor, Inc. | ||
| NCT02725515 | A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus | Phase 2 Interventional | Xencor, Inc. | ||